How Sleep Apnea Disrupts Breathing and Long-Term Health

Hundreds of Micro-Suffocations Every Night

In severe obstructive sleep apnea (OSA), breathing can stop and restart more than 30 times per hour — over 240 times in a single eight-hour night. Each episode can last 10 to 60 seconds. The American Academy of Sleep Medicine estimates that OSA affects approximately 26% of adults aged 30–70 in the United States, with up to 80% of moderate-to-severe cases going undiagnosed. The consequences extend far beyond snoring: untreated sleep apnea is independently associated with hypertension, heart disease, stroke, type 2 diabetes, and premature death.

Two Distinct Types of Sleep Apnea

Sleep apnea is not a single disease. The two primary forms have entirely different origins, though their downstream effects overlap considerably.

Obstructive Sleep Apnea (OSA)

OSA — accounting for 84% of cases — results from physical collapse of the upper airway during sleep. Muscle tone throughout the body decreases during sleep, including in the pharyngeal dilator muscles that normally hold the throat open. In susceptible individuals, this relaxation allows soft tissues — the soft palate, uvula, tongue base, and pharyngeal walls — to collapse inward, partially (hypopnea) or completely (apnea) blocking airflow.

Central Sleep Apnea (CSA)

CSA is neurological. The brainstem's respiratory control centers fail to send adequate signals to the diaphragm and intercostal muscles during sleep. No obstruction is present — the airway is open, but breathing effort simply stops. CSA is associated with heart failure, stroke, and the use of opioid medications, which depress the brainstem's chemoreceptor sensitivity to rising CO2.

The Physiology of an Apnea Event

During an obstructive episode, the sleeping person continues trying to breathe against a closed airway. Intrathoracic pressure swings become enormous — up to −90 cmH2O in severe cases — as respiratory muscles strain against the obstruction. Blood oxygen levels (SpO2) drop, sometimes below 70% in severe OSA. Carbon dioxide rises.

The brain detects hypoxia and hypercapnia through peripheral and central chemoreceptors and triggers an arousal — a brief awakening that restores muscle tone and reopens the airway. The person typically does not remember these arousals, but each one fragments sleep architecture, preventing restorative slow-wave and REM sleep. The arousal also triggers a sympathetic nervous system surge: heart rate spikes, blood pressure rises sharply, and stress hormones (cortisol, norepinephrine) flood the circulation. Repeated hundreds of times a night, this becomes a major cardiovascular stressor.

Diagnostic Criteria and Testing

Diagnosis relies on measuring the Apnea-Hypopnea Index (AHI) — the average number of apnea and hypopnea events per hour of sleep.

Gold-standard diagnosis is in-laboratory polysomnography (PSG), which simultaneously records EEG, EMG, ECG, airflow, respiratory effort, and oximetry. Home sleep apnea tests (HSAT) are now widely used for patients with high pretest probability and no complex comorbidities.

Risk Factors

• Obesity — the single strongest risk factor; fat deposits in the pharyngeal walls narrow the airway lumen. A 10% weight gain increases OSA risk by 32%
• Male sex — men have anatomically longer pharynges and different fat distribution; OSA is 2–3 times more prevalent in men than premenopausal women
• Menopause — OSA prevalence in women rises sharply after menopause, suggesting protective effects of progesterone on upper airway muscle tone
• Craniofacial anatomy — retrognathia (recessed jaw), macroglossia, and adenotonsillar hypertrophy reduce airway size
• Alcohol and sedatives — relax pharyngeal muscles and suppress arousal responses, worsening both frequency and duration of events

Long-Term Health Consequences

The cyclic hypoxia, sleep fragmentation, and sympathetic surges of untreated OSA create systemic damage. The Wisconsin Sleep Cohort Study, which followed participants for 18 years, found that severe untreated OSA was associated with a 3-fold increase in all-cause mortality compared with non-OSA controls.

• Hypertension: OSA causes sustained elevation of daytime blood pressure; it is the most common secondary cause of treatment-resistant hypertension
• Atrial fibrillation: Negative intrathoracic pressure stretches atrial walls, triggering electrical remodeling that predisposes to AFib
• Metabolic disease: Intermittent hypoxia impairs insulin signaling and promotes hepatic glucose output, independently worsening glycemic control
• Cognitive decline: Research suggests OSA accelerates beta-amyloid deposition, linking it to Alzheimer's disease risk

Treatment Options

CPAP therapy is effective when used consistently — studies show it reduces systolic blood pressure by 2–3 mmHg on average, lowers daytime sleepiness scores, and reduces cardiovascular event rates in patients with established coronary artery disease.

This article is for informational purposes only. Consult a qualified healthcare professional for medical advice.